<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158204">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02080793</url>
  </required_header>
  <id_info>
    <org_study_id>LEJEUNE-CORMIER INCA 2012</org_study_id>
    <nct_id>NCT02080793</nct_id>
  </id_info>
  <brief_title>STUDY OF PREFERENCES IN MEN FACED WITH THE DIFFERENT TREATMENT OPTIONS FOR LOCALIZED PROSTRATE CANCER WITH A GOOD OR INTERMEDIATE PROGNOSIS</brief_title>
  <acronym>CALIPSO</acronym>
  <official_title>STUDY OF PREFERENCES IN MEN FACED WITH THE DIFFERENT TREATMENT OPTIONS FOR LOCALIZED PROSTRATE CANCER WITH A GOOD OR INTERMEDIATE PROGNOSIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be based on two questionnaires

        1. One specific questionnaire that has already been developed from social sciences
           interviews conducted in men who have been treated for localized prostrate cancer, with
           a good or intermediate prognosis. This questionnaire comprises 11 pairs of scenarios.
           Each scenario gathers in a random manner, the modalities of 7 possible characteristics
           of the management strategy for localized prostrate cancer, with a good or intermediate
           prognosis:

             -  the risk of death at 5 years (modalities: 5%, 15%),

             -  the risk of impotence (modalities: 0%, 25%, 50%, 75%),

             -  the presence of urinary leaks (modalities: no protection during the day, one
                protection pad per day, several protection pads per day),

             -  the duration and frequency of care provided (modalities: 2 days of care in your
                whole life, 7 days of care in your whole life, 5 half-days of care per week for 8
                weeks, every 3 months for 2 years then every 6 months for life),

             -  ablation of the prostate (modalities: Yes, No),

             -  the existence of possible treatments in case of aggravation or recurrence
                (modalities: Yes, No),

             -  the nature of the technology used (modalities: innovative technology, standard
                technology).

           The objective is to ask each participant of the study for each pair of scenarios, to
           choose from the two scenarios (binary-choice survey), the scenario he prefers.

        2. The &quot;Spielberger Inventory Trait&quot; scale to evaluate stable characteristics in the
           propensity to anxiety in study participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Identification of personal factors  linked to the management strategy chosen with regard to the preferences of patients.</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <enrollment type="Anticipated">680</enrollment>
  <condition>Patients Seen at a Urology Consultation</condition>
  <arm_group>
    <arm_group_label>Patients phase pilote</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients phase réelle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <arm_group_label>Patients phase pilote</arm_group_label>
    <arm_group_label>Patients phase réelle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men:

          -  aged 50 to 70 years

          -  seen at a urology consultation

          -  able to understand written and spoken French

          -  who have provided written informed consent

        Exclusion Criteria:

        Men:

          -  under guardianship or wards of court

          -  who have already been diagnosed withor treated for prostrate cancer

          -  with recently diagnosed cancer or on treatment for this cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luc CORMIER</last_name>
    <phone>3.80.29.37.61</phone>
    <phone_ext>+33</phone_ext>
    <email>luc.cormier@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique St Marie</name>
      <address>
        <city>Chalon-sur-saone</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel DELORME</last_name>
      <phone>3 85 90 03 77</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc CORMIER</last_name>
      <phone>3.80.29.37.61</phone>
      <phone_ext>+33</phone_ext>
      <email>luc.cormier@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital TENON</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CUSSENOT</last_name>
      <phone>: 1 56 01 64 95</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de TOURS</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck BRUYERE</last_name>
      <phone>2 47 47 47 47</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
